We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Investors Want Abbott To Explain Delay In Alere Deal

Law360, New York (January 12, 2018, 4:36 PM EST) -- Abbott Laboratories must turn over documents related to its motive for balking at and then renegotiating its $5.3 billion purchase of Alere Inc., Alere investors said Thursday in Massachusetts federal court, arguing that Abbott’s reasoning is key to their stock drop lawsuit against Alere.

In support of their motion to compel, the proposed class of investors told court that a central issue in the securities fraud dispute is whether, and to what extent, problems with Alere’s INRatio blood clotting measurement system motivated Abbott’s reluctance to proceed...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.